Comparing citrate and heparin to prevent clotting during dialysis
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares two ways to prevent blood from clotting during a type of dialysis called hemodiafiltration. You may get either a standard drug (heparin) or a newer approach using citrate to keep your dialysis filter from clotting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have end-stage kidney disease and are on regular hemodialysis three times a week.
- You have a working arteriovenous (AV) fistula, which is a connection between an artery and vein used for dialysis.
- You are not currently taking blood thinners (anticoagulants) or two antiplatelet drugs together (like aspirin and clopidogrel).
- You do not have a bleeding disorder, active bleeding, or acute kidney injury.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two blood-thinning medications used during continuous dialysis for acute kidney injury: one uses citrate (a chemical that prevents clotting) and the other uses heparin (a standard blood thinner). By looking at how well these treatments work, the study aims to find the safest and most effective way to keep the dialysis filter working.
This study compares two ways to prevent blood clots during kidney dialysis in people with sepsis-related kidney failure. The goal is to see which method is safer and works better to keep the dialysis filter working properly.
This study compares different patterns of continuous kidney dialysis (called CRRT) to see how they affect calcium levels in the blood when using a citrate-based blood thinner. It may help find the safest way to manage calcium during treatment.
This study tests whether dialysis can be done safely without using heparin (a blood thinner) in people with end-stage kidney disease. If successful, it could reduce the need for blood-thinning medications and their associated risks.
This study tests a special blood-filtering treatment for patients in the intensive care unit (ICU) with acute kidney injury. It uses a medicine called citrate to prevent blood clotting during dialysis, which may be safer for patients whose liver cannot process citrate normally.
This trial looks at whether a blood thinner called citrate is safe and effective in patients who have both kidney and liver failure while on continuous dialysis in the ICU. It may help guide treatment for people with serious organ problems.
Hear when a new End Stage Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.